Full-Time

Molecular Pathologist

Posted on 11/15/2024

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

AI & Machine Learning
Biotechnology
Healthcare

Senior

Chicago, IL, USA + 1 more

More locations: Research Triangle, Durham, NC, USA

Hybrid position requiring some in-office presence.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • MD with a current medical license and board-certified in Anatomic Pathology and/or Clinical Pathology, with board certification or eligibility in Molecular Genetic Pathology
  • Clinical experience with next generation sequencing interpretation
  • Detailed knowledge and experience in oncology, cancer immunotherapy, medical immunology and clinical research, preferred
  • Excellent managerial, organizational, reporting and communication skills
  • Experience working in a regulated clinical laboratory environment (CLIA/CAP/NYSDOH/QSR)
  • Experience ensuring compliance of a clinical laboratory to regulatory standards
Responsibilities
  • Evaluate NGS sequencing results
  • Conduct pathology review including IHC for both research and clinical specimens
  • Participate in clinical report review and delivery
  • Collaborate with multi-disciplinary team focused on answering key biological questions
  • Work to establish and maintain CLIA/CAP compliance in a novel field

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights.

Company Stage

IPO

Total Funding

$894.9M

Headquarters

Chicago, Illinois

Founded

2015

Growth & Insights
Headcount

6 month growth

5%

1 year growth

15%

2 year growth

36%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus's IPO and significant revenue generation indicate strong financial health and growth potential.
  • Collaborations with industry giants like SoftBank and United Therapeutics can lead to groundbreaking advancements and increased market share.
  • The company's focus on personalized therapy and AI-driven insights can significantly improve patient outcomes, making it a rewarding place to work for those passionate about healthcare innovation.

What critics are saying

  • The lawsuit from Guardant Health over patent infringement could result in financial and reputational damage.
  • Operating in a highly competitive market with peers like Foundation Medicine and Guardant Health requires continuous innovation to maintain a competitive edge.

What makes Tempus unique

  • Tempus leverages AI to provide actionable insights from medical data, setting it apart from competitors who may not integrate AI as deeply into their platforms.
  • Their focus on personalized therapy options and extensive cancer research, including a pan-cancer organoid platform and liquid biopsy assay, distinguishes them in the healthcare tech space.
  • Tempus's collaboration with major firms like SoftBank and United Therapeutics highlights its strong industry partnerships and credibility.

Help us improve and share your feedback! Did you find this helpful?